Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would a BRAF V600E mutation affect your decision to give adjuvant therapy in a patient with lung cancer?
Related Questions
How does metaplastic thymoma histology impact your decision regarding adjuvant radiation?
In patients with IV NSCLC and EGFR mutation, is there a cutoff on the % of allele frequency that is considered to be too low to be actionable?
Would you switch from carboplatin/etoposide to cisplatin/etoposide in an LS-SCLC patient who initially declines cisplatin but subsequently agrees to it?
How would you treat a patient with metastatic NSCLC, adenocarcinoma subtype with BRAF V600K mutation, PD-L1 >50% with progression on 1st line chemo-immunotherapy?
Would you add immunotherapy to chemotherapy for a patient with metastatic NSCLC, an atypical EGFR mutation, and PD-L1 ≥50% who has progressed on osimertinib?
In ES-SCLC presenting with extensive brain metastases, how do you time whole brain radiation after the first cycle of chemotherapy has already been delivered?
In a patient with potentially resectable lung cancer experiencing severe pain due to chest wall invasion, would you consider palliative radiation therapy prior to neoadjuvant/perioperative chemoimmunotherapy?
Should a patient with resected stage IIIA lung adenocarcinoma harboring an STK11 mutation receive adjuvant immune checkpoint inhibitor therapy following the completion of adjuvant chemotherapy?
How would you approach treatment for EGFR-mutant NSCLC with acquired ERBB2 mutation and amplification as resistance to prior osimertinib-based therapy?
How do you typically approach adjuvant therapy for a Masaoka stage IVa thymoma post-R0 resection?
